In addition, three glucose metabolism-related genes (SERPINE1, VCAN, and TFPI2) may be potential targets for the immunotherapy of patients with NAFLD-hepatocellular carcinoma. The gene discussed is TFPI2; the disease is metabolic dysfunction-associated steatotic liver disease.